{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:27:22Z","timestamp":1790108842069,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40264-025-01603-z","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T11:34:17Z","timestamp":1756640057000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["R Value-Based Criteria Outperform Alkaline Phosphatase Less than Twice Normal in Identifying Hy\u2019s Law Cases in Clinical Trials"],"prefix":"10.1007","volume":"49","author":[{"given":"Jasmine","family":"Amirzadegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwige Chiogo","family":"Vouffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Navarro Almario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-1020","authenticated-orcid":false,"given":"Paul H.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"1603_CR1","unstructured":"Zimmerman H. Drug-induced liver disease. In: Hepatotoxicity, the adverse effects of drugs and other chemicals on the liver, 2nd edn. 1999. p. 432\u20133."},{"issue":"2","key":"1603_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1055\/s-0034-1375961","volume":"34","author":"MI Avigan","year":"2014","unstructured":"Avigan MI. DILI and drug development: a regulatory perspective. Semin Liver Dis. 2014;34(2):215\u201326. https:\/\/doi.org\/10.1055\/s-0034-1375961.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"1603_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E Bjornsson","year":"2005","unstructured":"Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481\u20139. https:\/\/doi.org\/10.1002\/hep.20800.","journal-title":"Hepatology"},{"issue":"1","key":"1603_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","volume":"147","author":"RJ Fontana","year":"2014","unstructured":"Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96-108 e4. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.045.","journal-title":"Gastroenterology"},{"issue":"1","key":"1603_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","volume":"147","author":"M Robles-Diaz","year":"2014","unstructured":"Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109-118 e5. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.050.","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"1603_CR6","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s40264-014-0182-7","volume":"37","author":"JR Senior","year":"2014","unstructured":"Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):S9-17. https:\/\/doi.org\/10.1007\/s40264-014-0182-7.","journal-title":"Drug Saf"},{"key":"1603_CR7","unstructured":"FDA. Drug-induced liver injury: premarketing clinical evaluation. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation. 2009."},{"key":"1603_CR8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003145","author":"ASt Barritt","year":"2024","unstructured":"Barritt ASt, Hayashi PH, Stolz AA, Barnhart H, Hoofnagle JH, Drug-Induced Liver Injury N. Refinement of Hy law using the Drug-Induced Liver Injury Network database. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000003145.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"1603_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.29283","volume":"66","author":"PH Hayashi","year":"2017","unstructured":"Hayashi PH, Rockey DC, Fontana RJ, et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017;66(4):1275\u201385. https:\/\/doi.org\/10.1002\/hep.29283.","journal-title":"Hepatology"},{"issue":"11","key":"1603_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs\u2013I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323\u201330. https:\/\/doi.org\/10.1016\/0895-4356(93)90101-6.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1603_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55\u201368. https:\/\/doi.org\/10.2165\/00002018-200932010-00005.","journal-title":"Drug Saf"},{"issue":"5","key":"1603_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/hep.20703","volume":"41","author":"J Polson","year":"2005","unstructured":"Polson J, Lee WM, American Association for the Study of Liver D. Aasld position paper: the management of acute liver failure. Hepatology. 2005;41(5):1179\u201397. https:\/\/doi.org\/10.1002\/hep.20703.","journal-title":"Hepatology"},{"issue":"5","key":"1603_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","volume":"66","author":"J Wendon","year":"2017","unstructured":"European Association for the Study of the Liver, Wendon J, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047\u201381. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.003.","journal-title":"J Hepatol"},{"issue":"1","key":"1603_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376. https:\/\/doi.org\/10.1002\/hep.22322.","journal-title":"Hepatology"},{"key":"1603_CR15","unstructured":"Obeticholic acid for the treatment of adult patients with pre\u2010cirrhotic liver fibrosis due to non\u2010alcoholic steatohepatitis (NASH). Food and Drug Administration; 2023. https:\/\/www.fda.gov\/media\/168327\/download."},{"issue":"4611","key":"1603_CR16","first-page":"S1444","volume":"76","author":"E Chiogo Vouffo","year":"2022","unstructured":"Chiogo Vouffo E, Lan L, Pei V, Avigan MI, Hayashi PH. Characteristics of DILI in clinical trials: initial experience of the FDA Drug-Induced Liver Team. Hepatology. 2022;76(4611):S1444\u20135.","journal-title":"Hepatology"},{"key":"1603_CR17","unstructured":"Lowe D, Sanvictores T, Zubair M, John S. Alkaline phosphatase. StatPearls. 2025."},{"key":"1603_CR18","unstructured":"Pexidartinib for tenosynovial giant cell tumor. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211810Orig1s000MultidisciplineR.pdf."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01603-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:28:07Z","timestamp":1769837287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01603-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01603-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Participation Program at the US Food and Drug Administration administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the US Food and Drug Administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The conclusions and views in this manuscript are the authors and do not represent an official position of the Food and Drug Administration, the Department of Health and Human Services, or the US Government.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Not applicable. Only de-identified data are used.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. Only de-identified data used.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Data sharing is not permitted by the FDA. Data are proprietary to drug developers.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JA: study design, data analysis, manuscript writing; ECV: data acquisition, data analysis; LL: data acquisition; EN: study design, data analysis, manuscript writing; MIA: study design, manuscript writing; PHH: data acquisition; study design, data analysis, manuscript. All authors read and approved the final version of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}